Cabotegravir/rilpivirine (Cabenuva) vs Tenofovir alafenamide/emtricitabine
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV reverse transcriptase · full HIV pipeline
Cabotegravir/rilpivirine (Cabenuva)
Marketed by GlaxoSmithKline
NCT05917509 · Phase 3 · completed
The 171 participants were assigned to active treatment groups without randomization or blinding, which limits the reliability of comparisons between the regimens. The primary outcomes measured virologic suppression. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: March 2027 · NCT06411223 (registry estimate)
Reported efficacy
Percentage of Participants With Plasma Human Immunodeficiency Virus-ribonucleic Acid (HIV-RNA) >=50 Copies Per Milliliter (c/mL) as Per Food and Drug Administration (FDA) Snapshot Algorithm at Week 48: HIV-1 RNA >=50 copies/mL (FDA Snapshot) at Week 48, cabotegravir LA + rilpivirine LA every 8 weeks vs every 4 weeks: 1.7% vs 1.0%, adjusted difference 0.8% (95% CI -0.6 to 2.2); non-inferior against the 4% margin (CT.gov posted results). (met)
Result source: NCT03299049
Tenofovir alafenamide/emtricitabine · Descovy
Marketed by Gilead Sciences
NCT02121795 · Phase 3 · completed
This was a randomized, quadruple-blind, active-controlled trial of 668 participants, with 333 receiving F/TAF and 330 receiving FTC/TDF in the treated analysis. The primary clinical endpoint was met: virologic suppression was 94.3% versus 93.0%, and the prespecified non-inferiority confidence interval remained within the 10% margin.
Next expected readout: January 2027 · NCT07349758 (registry estimate)
Reported efficacy
Incidence of HIV-1 Infection Per 100 Person Years (PY) (When all participants completed minimum follow-up of 48 weeks and at least 50% of the participants completed 96 weeks of follow-up after randomization or permanently discontinued from the study (maximum 125 weeks)): Incidence of HIV-1 Infection Per 100 Person Years (PY) (When all participants completed minimum follow-up of 48 weeks and at least 50% of the participants completed 96 weeks of follow-up after randomization or permanently discontinued from the study (maximum 125 weeks)): Descovy (DVY) 0.16 HIV-1 infections per 100 PY (95% CI 0.064 to 0.33) | Truvada (TVD) 0.342 HIV-1 infections per 100 PY (95% CI 0.191 to 0.564) (met)
Result source: NCT02842086
Results for HIV
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Cabotegravir/rilpivirine (Cabenuva) | Tenofovir alafenamide/emtricitabine |
|---|---|---|
| HIV-1 RNA below 50 copies/mL (week 48) | 94% vs 91%vs CAB 30 mg+ABC/3TCNCT02120352125 other results
| 94.3% vs 93%vs FTC/TDFNCT0212179531 other results
|
| HIV-1 RNA 50 copies/mL or more (week 48) | 0% vs 0%vs DTG + RPVNCT03639311 | 0.4% vs 1.1%vs DTG + F/TAFNCT031103802 other results
|
| CD4 count, change (week 48) | 270.6 vs 369.9vs CAB 30 mg+ABC/3TCNCT0212035236 other results
| 60 vs 42vs Baseline Treatment Regimen (SBR)NCT0181573636 other results
|
HIV-1 RNA below 50 copies/mL (week 48)
- Cabotegravir/rilpivirine (Cabenuva)
- 94% vs 91%vs CAB 30 mg+ABC/3TCNCT02120352
125 other results
- 95% vs 91% NCT02120352
- 80% vs 71% NCT01641809
- 87% vs 71% NCT01641809
- 80% vs 71% NCT01641809
- 67% vs 0% NCT01641809
- 70% vs 0% NCT01641809
- 63% vs 0% NCT01641809
- 73% vs 0% NCT01641809
- 65% vs 0% NCT01641809
- 72% vs 0% NCT01641809
- 67% vs 0% NCT01641809
- 75% vs 63% NCT01641809
- 65% vs 0% NCT01641809
- 85% vs 83% NCT01641809
- 75% vs 68% NCT01641809
- 62% vs 0% NCT01641809
- 85% vs 89% NCT01641809
- 73% vs 68% NCT01641809
- 63% vs 0% NCT01641809
- 83% vs 89% NCT01641809
- 73% vs 68% NCT01641809
- 63% vs 0% NCT01641809
- 83% vs 89% NCT01641809
- 80% vs 71% NCT01641809
- 62% vs 0% NCT01641809
- 91% vs 94% NCT01641809
- 82% vs 68% NCT01641809
- 92% vs 89% NCT01641809
- 82% vs 71% NCT01641809
- 62% vs 0% NCT01641809
- 92% vs 94% NCT01641809
- 80% vs 69% NCT01641809
- 91% vs 91% NCT01641809
- 78% vs 69% NCT01641809
- 89% vs 91% NCT01641809
- 75% vs 66% NCT01641809
- 85% vs 87% NCT01641809
- 85% vs 74% NCT01641809
- 62% vs 0% NCT01641809
- 94% vs 96% NCT01641809
- 62% vs 0% NCT01641809
- 62% vs 0% NCT01641809
- 60% vs 0% NCT01641809
- 52% vs 0% NCT01641809
- 77% vs 0% NCT01641809
- 80% vs 0% NCT01641809
- 80% vs 0% NCT01641809
- 80% vs 0% NCT01641809
- 75% vs 0% NCT01641809
- 80% vs 0% NCT01641809
- 75% vs 0% NCT01641809
- 84% vs 63% NCT01641809
- 74% vs 0% NCT01641809
- 93% vs 83% NCT01641809
- 85% vs 68% NCT01641809
- 75% vs 0% NCT01641809
- 95% vs 89% NCT01641809
- 85% vs 68% NCT01641809
- 77% vs 0% NCT01641809
- 95% vs 89% NCT01641809
- 85% vs 68% NCT01641809
- 75% vs 0% NCT01641809
- 95% vs 89% NCT01641809
- 87% vs 71% NCT01641809
- 74% vs 0% NCT01641809
- 96% vs 94% NCT01641809
- 85% vs 68% NCT01641809
- 95% vs 89% NCT01641809
- 85% vs 71% NCT01641809
- 75% vs 0% NCT01641809
- 95% vs 94% NCT01641809
- 87% vs 69% NCT01641809
- 96% vs 91% NCT01641809
- 85% vs 69% NCT01641809
- 95% vs 91% NCT01641809
- 85% vs 66% NCT01641809
- 95% vs 87% NCT01641809
- 87% vs 74% NCT01641809
- 75% vs 0% NCT01641809
- 96% vs 96% NCT01641809
- 70% vs 0% NCT01641809
- 74% vs 0% NCT01641809
- 70% vs 0% NCT01641809
- 70% vs 0% NCT01641809
- 58% vs 0% NCT01641809
- 62% vs 0% NCT01641809
- 58% vs 0% NCT01641809
- 65% vs 0% NCT01641809
- 57% vs 0% NCT01641809
- 68% vs 0% NCT01641809
- 58% vs 0% NCT01641809
- 68% vs 63% NCT01641809
- 57% vs 0% NCT01641809
- 79% vs 83% NCT01641809
- 72% vs 68% NCT01641809
- 55% vs 0% NCT01641809
- 83% vs 89% NCT01641809
- 72% vs 68% NCT01641809
- 55% vs 0% NCT01641809
- 83% vs 89% NCT01641809
- 78% vs 68% NCT01641809
- 53% vs 0% NCT01641809
- 90% vs 89% NCT01641809
- 80% vs 71% NCT01641809
- 50% vs 0% NCT01641809
- 92% vs 94% NCT01641809
- 83% vs 68% NCT01641809
- 96% vs 89% NCT01641809
- 85% vs 71% NCT01641809
- 52% vs 0% NCT01641809
- 98% vs 94% NCT01641809
- 83% vs 69% NCT01641809
- 96% vs 91% NCT01641809
- 85% vs 69% NCT01641809
- 98% vs 91% NCT01641809
- 78% vs 66% NCT01641809
- 90% vs 87% NCT01641809
- 87% vs 74% NCT01641809
- 53% vs 0% NCT01641809
- 96% vs 96% NCT01641809
- 52% vs 0% NCT01641809
- 50% vs 0% NCT01641809
- 52% vs 0% NCT01641809
- 52% vs 0% NCT01641809
- 98% vs 100% NCT03639311
- Tenofovir alafenamide/emtricitabine
- 94.3% vs 93%vs FTC/TDFNCT02121795
31 other results
- 88.6% vs 92.4% NCT02469246
- 91.6% vs 88.5% NCT01797445
- 92.4% vs 93% NCT02607930
- 87.2% vs 80.8% NCT01705574
- 93.4% vs 97.8% NCT02605954
- 96.6% vs 97.8% NCT02605954
- 81.5% vs 84.1% NCT02607930
- 88.6% vs 89.1% NCT02121795
- 82.1% vs 88.4% NCT02469246
- 84% vs 82.3% NCT01797445
- 92.8% vs 89.1% NCT01815736
- 87.9% vs 89.8% NCT02607930
- 93.3% vs 91.1% NCT03110380
- 90.4% vs 92% NCT04143594
- 84.9% vs 92% NCT04143594
- 84.6% vs 92% NCT04143594
- 96.9% vs 93.9% NCT02397694
- 88.4% vs 89.7% NCT01497899
- 74.8% vs 74% NCT01565850
- 86.5% vs 92% NCT04143594
- 75.5% vs 92% NCT04143594
- 86.5% vs 92% NCT04143594
- 96.9% vs 90.9% NCT02397694
- 88.4% vs 87.9% NCT01497899
- 76.7% vs 84% NCT01565850
- 90.4% vs 96% NCT04143594
- 88.7% vs 96% NCT04143594
- 88.5% vs 96% NCT04143594
- 94.2% vs 100% NCT04143594
- 92.5% vs 100% NCT04143594
- 94.2% vs 100% NCT04143594
HIV-1 RNA 50 copies/mL or more (week 48)
- Cabotegravir/rilpivirine (Cabenuva)
- 0% vs 0%vs DTG + RPVNCT03639311
- Tenofovir alafenamide/emtricitabine
- 0.4% vs 1.1%vs DTG + F/TAFNCT03110380
2 other results
- 1.8% vs 0.7% NCT02469246
- 2.5% vs 1.1% NCT02469246
CD4 count, change (week 48)
- Cabotegravir/rilpivirine (Cabenuva)
- 270.6 vs 369.9vs CAB 30 mg+ABC/3TCNCT02120352
36 other results
- 263.7 vs 346.1 NCT02120352
- 257.5 vs 369.9 NCT02120352
- 264.4 vs 346.1 NCT02120352
- 267.5 vs 281.7 NCT01641809
- 287 vs 279.4 NCT01641809
- 201.4 vs 257.1 NCT01641809
- 269.4 vs 263.8 NCT01641809
- 241.6 vs 262.5 NCT01641809
- 212.8 vs 221.5 NCT01641809
- 213 vs 185.2 NCT01641809
- 205.2 vs 197.4 NCT01641809
- 188.1 vs 178.2 NCT01641809
- 177.7 vs 166.4 NCT01641809
- 180.9 vs 143.4 NCT01641809
- 286.2 vs 281.7 NCT01641809
- 278.1 vs 279.4 NCT01641809
- 254 vs 257.1 NCT01641809
- 266.1 vs 263.8 NCT01641809
- 259 vs 262.5 NCT01641809
- 212.3 vs 221.5 NCT01641809
- 265 vs 185.2 NCT01641809
- 209.9 vs 197.4 NCT01641809
- 193.3 vs 178.2 NCT01641809
- 194.7 vs 166.4 NCT01641809
- 204 vs 143.4 NCT01641809
- 269.4 vs 281.7 NCT01641809
- 261.5 vs 279.4 NCT01641809
- 232 vs 257.1 NCT01641809
- 217.7 vs 263.8 NCT01641809
- 235.1 vs 262.5 NCT01641809
- 203.6 vs 221.5 NCT01641809
- 192 vs 185.2 NCT01641809
- 191.4 vs 197.4 NCT01641809
- 205 vs 178.2 NCT01641809
- 186.4 vs 166.4 NCT01641809
- 172.5 vs 143.4 NCT01641809
- Tenofovir alafenamide/emtricitabine
- 60 vs 42vs Baseline Treatment Regimen (SBR)NCT01815736
36 other results
- 50 vs 46 NCT02121795
- -29 vs 10 NCT02469246
- 274 vs 260 NCT01797445
- 237 vs 281 NCT02607956
- 287 vs 288 NCT02607930
- 20 vs 21 NCT02121795
- -30 vs 2 NCT02469246
- 225 vs 200 NCT01797445
- 180 vs 201 NCT02607956
- 278 vs 289 NCT02607956
- 235 vs 228 NCT02607930
- 299 vs 317 NCT02607930
- 18 vs 36 NCT03110380
- 221 vs 212 NCT01705574
- 56 vs -1 NCT02616783
- 5 vs 41 NCT01968551
- 48 vs -4 NCT02616783
- -28 vs 8 NCT02605954
- -23 vs 8 NCT02605954
- 23 vs 12 NCT01968551
- 275 vs 248 NCT04143594
- 262 vs 248 NCT04143594
- 245 vs 248 NCT04143594
- 204 vs 193 NCT04143594
- 213 vs 193 NCT04143594
- 220 vs 193 NCT04143594
- 177 vs 204 NCT01497899
- 231 vs 212 NCT01565850
- 195 vs 232 NCT04143594
- 220 vs 232 NCT04143594
- 211 vs 232 NCT04143594
- 172 vs 163 NCT04143594
- 158 vs 163 NCT04143594
- 206 vs 163 NCT04143594
- 165 vs 179 NCT01497899
- 186 vs 139 NCT01565850
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
6 other shared endpoints and safety
Coverage. Cabotegravir/rilpivirine (Cabenuva): 10 of 10 rows · Tenofovir alafenamide/emtricitabine: 10 of 10 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Cabotegravir/rilpivirine (Cabenuva) Rows use multiple source trials | Tenofovir alafenamide/emtricitabine Rows use multiple source trials |
|---|---|---|
| CD4+ absolute change · cells/uL No placebo or comparator arm | 276 cells/uL @ 324wk30 mga,b,c,d,e NCT01641809 · Phase 2 · registry result, not featured evidence · pooled show 2 more doses272 cells/uL @ 324wk60 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled 402 cells/uL @ 324wk10 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled | 224 cells/uL @ 48wka,b,c,d,e NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3 show 2 more doses-66 cells/uL @ 48wk NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3 -179 cells/uL @ 48wk NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3 |
| HIV-1 RNA absolute change · log Induction | -2.634 vs -2.533 Efavirenz log @ 12wk30 mga,c,d NCT01641809 · Phase 2 · registry result, not featured evidence · pooled show 2 more doses-2.79 vs -2.533 Efavirenz log @ 12wk60 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled -2.793 vs -2.533 Efavirenz log @ 12wk10 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled | -3.03 vs -3.15 DTG + F/TAF log @ 12wkc,d NCT02397694 · Phase 2 · registry result, not featured evidence · combination |
| HIV-1 RNA absolute change · log Maintenance | -2.89 vs -2.77 CAB 30 mg+ABC/3TC log @ 96wkIM-Q4Wa,f,c,g NCT02120352 · Phase 2 · registry result, not featured evidence · combination show 1 more dose-2.77 vs -2.77 CAB 30 mg+ABC/3TC log @ 96wkIM-Q8W NCT02120352 · Phase 2 · registry result, not featured evidence · combination | -3.08 vs -3.1 DTG + F/TAF log @ 96wkf,c,g NCT02607956 · Phase 3 · registry result, not featured evidence · HIV · phase 3 1 other source trial-3.09 vs -3.1 ABC/DTG/3TC log @ 96wk NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3 |
| HIV-1 RNA absolute change · log No placebo or comparator arm | -2.215 log @ 324wk30 mga,f,c,d,e NCT01641809 · Phase 2 · registry result, not featured evidence · pooled show 2 more doses-2.438 log @ 324wk60 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled -2.488 log @ 324wk10 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled | -3.04 log @ 48wkf,c,d,e NCT01967940 · Phase 3 · registry result, not featured evidence · combination |
| HIV-1 RNA Less Than 50 Copies responder rate · % of participants Induction | 75% (n=60) vs 61% (n=62) Efavirenz @ 12wk30 mga,f,c,g NCT01641809 · Phase 2 · registry result, not featured evidence · pooled show 2 more doses82% (n=61) vs 61% (n=62) Efavirenz @ 12wk60 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled 88% (n=60) vs 61% (n=62) Efavirenz @ 12wk10 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled | 96.6% (n=89) vs 98.9% (n=91) ABC/3TC+3rd Agent @ 12wka,f,c,g NCT02605954 · Phase 3 · registry result, not featured evidence show 1 more dose95.1% (n=183) vs 98.9% (n=91) ABC/3TC+3rd Agent @ 12wk NCT02605954 · Phase 3 · registry result, not featured evidence |
| HIV-1 RNA Less Than 50 Copies responder rate · % of participants No placebo or comparator arm | 87% (n=430) @ 52wkc,g,h NCT04399551 · Phase 3 · registry result, not featured evidence | 81.4% (n=242) @ 144wka,c,g,h NCT01818596 · Phase 3 show 1 more dose100% (n=6) @ 144wk NCT01818596 · Phase 3 |
| Dropout rate | 13.6%i NCT04982445 · Phase 4 · registry result, not featured evidence show 45 more results—400 mg + 600 mg Q4W NCT05896748 · Phase 3 · registry result, not featured evidence · combination —400 mg + 600 mg Q4W NCT05896748 · Phase 3 · registry result, not featured evidence · combination —400 mg + 600 mg Q4W NCT05896748 · Phase 3 · registry result, not featured evidence · combination 1.1%400 mg + 600 mg Q4W NCT05896748 · Phase 3 · registry result, not featured evidence · combination 8.6%Direct to Injections (D2I) NCT04542070 · Phase 3 · registry result, not featured evidence 13.1%Oral lead-in Phase (OLI) NCT04542070 · Phase 3 · registry result, not featured evidence —Q2M NCT04542070 · Phase 3 · registry result, not featured evidence 6.5% NCT04399551 · Phase 3 · registry result, not featured evidence 11.3% NCT04001803 · Phase 3 · registry result, not featured evidence 1.3%CAB LA + VRC07-523LS NCT03739996 · Phase 2 · registry result, not featured evidence · combination —Step 2: CAB LA + VRC07-523LS NCT03739996 · Phase 2 · registry result, not featured evidence · combination —IM-Q4W NCT02120352 · Phase 2 · registry result, not featured evidence · combination —IM-Q4W NCT02120352 · Phase 2 · registry result, not featured evidence · combination —IM-Q8W NCT02120352 · Phase 2 · registry result, not featured evidence · combination —IM-Q8W NCT02120352 · Phase 2 · registry result, not featured evidence · combination 15.6%Q2M NCT03639311 · Phase 2 · registry result, not featured evidence · combination 11.7%30 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled —30 mg NCT01641809 · Phase 2 · registry result, not featured evidence —30 mg NCT01641809 · Phase 2 · registry result, not featured evidence —30 mg NCT01641809 · Phase 2 · registry result, not featured evidence 9.8%60 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled —60 mg NCT01641809 · Phase 2 · registry result, not featured evidence —60 mg NCT01641809 · Phase 2 · registry result, not featured evidence —60 mg NCT01641809 · Phase 2 · registry result, not featured evidence 13.3%10 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled —10 mg NCT01641809 · Phase 2 · registry result, not featured evidence —10 mg NCT01641809 · Phase 2 · registry result, not featured evidence —10 mg NCT01641809 · Phase 2 · registry result, not featured evidence 12.5%30 mg NCT00920426 · Phase 2 · registry result, not featured evidence —5 mg NCT00920426 · Phase 2 · registry result, not featured evidence 15.2%30 mg NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 1 (C1) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 1 (C1) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 2 (C2) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 2 (C2) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 3 (C3) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 3 (C3) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 4 (C4) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 4 (C4) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 4h (C4h) CAB200 + r NCT04484337 · Phase 1 · registry result, not featured evidence · combination —Part 1: Cohort 4h (C4h) CAB400 + r NCT04484337 · Phase 1 · registry result, not featured evidence · combination —Part 2: Cohort 5 (C5) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 2: Cohort 5 (C5) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence —30 mg NCT03149848 · Phase 1 · registry result, not featured evidence —300 mg + 30 mg NCT03149848 · Phase 1 · registry result, not featured evidence · combination | 11.4%F/TAF + 3rd Agentj NCT02121795 · Phase 3 · combination show 52 more results—F/TAF + 3rd Agent (Double-Blind) NCT02121795 · Phase 3 · combination —Open-Label F/TAF From F/TAF NCT02121795 · Phase 3 —Open-Label F/TAF From FTC/TDF NCT02121795 · Phase 3 23.5%F/TAF NCT02469246 · Phase 3 —F/TAF (Double-Blind Phase) NCT02469246 · Phase 3 —Open-Label F/TAF From ABC/3TC NCT02469246 · Phase 3 —Open-Label F/TAF From F/TAF NCT02469246 · Phase 3 20%E/C/F/TAF NCT01797445 · Phase 3 —E/C/F/TAF (Double-Blind Phase) NCT01797445 · Phase 3 —Open-Label E/C/F/TAF From E/C/F/TA NCT01797445 · Phase 3 —Open-Label E/C/F/TAF From E/C/F/TD NCT01797445 · Phase 3 5.1%E/C/F/TAF NCT01815736 · Phase 3 —Extension Phase: E/C/F/TAF From E/ NCT01815736 · Phase 3 —Extension Phase: E/C/F/TAF From SB NCT01815736 · Phase 3 —Randomized Phase: E/C/F/TAF NCT01815736 · Phase 3 12.6%Cohort 1 (Treatment-experienced) NCT01818596 · Phase 3 0%Cohort 2 (Treatment-naive) NCT01818596 · Phase 3 4%Cohort 1: Age 12 to < 18 Years and NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3 1.9%Cohort 2: Age 6 to < 12 Years and NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3 0%Cohort 3: Age ≥ 2 Years and Weight NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3 4.4% NCT04782180 · Phase 4 · registry result, not featured evidence 18.7% NCT02607956 · Phase 3 · registry result, not featured evidence · HIV · phase 3 17.1%B/F/TAF NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —B/F/TAF to B/F/TAF NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3 7.4%B/F/TAF NCT03110380 · Phase 3 · registry result, not featured evidence —Double-Blind Treatment Phase B/F/T NCT03110380 · Phase 3 · registry result, not featured evidence —Open-label Extension Phase B/F/TAF NCT03110380 · Phase 3 · registry result, not featured evidence —Open-label Extension Phase B/F/TAF NCT03110380 · Phase 3 · registry result, not featured evidence · combination —DB STB to OL STB NCT01705574 · Phase 3 · registry result, not featured evidence —Double-Blind: STB NCT01705574 · Phase 3 · registry result, not featured evidence 5.4% NCT02616783 · Phase 3 · registry result, not featured evidence —Delayed E/C/F/TAF NCT02605954 · Phase 3 · registry result, not featured evidence 6.6%E/C/F/TAF NCT02605954 · Phase 3 · registry result, not featured evidence 5.3%E/C/F/TAF + LDV/SOF NCT02707601 · Phase 3 · registry result, not featured evidence · combination 5.4%F/R/TAF + LDV/SOF NCT02707601 · Phase 3 · registry result, not featured evidence · combination 0%Part 1 Randomized Cohort TAF NCT01967940 · Phase 3 · registry result, not featured evidence 0%Part 1 Sentinel Cohort TAF NCT01967940 · Phase 3 · registry result, not featured evidence —Part 2 E/C/F/TAF + ATV NCT01967940 · Phase 3 · registry result, not featured evidence · combination —HIV-Suppressed NCT02071082 · Phase 3 · registry result, not featured evidence —HIV/HBV Treatment-Naive NCT02071082 · Phase 3 · registry result, not featured evidence 9.1%Cohort 1: E/C/F/TAF+DRV NCT01968551 · Phase 3 · registry result, not featured evidence · combination 3.3%Cohort 2: E/C/F/TAF+DRV NCT01968551 · Phase 3 · registry result, not featured evidence · combination 8%E/C/F/TAF (12 - 17 Years of Age) NCT02276612 · Phase 2/3 · registry result, not featured evidence 0%E/C/F/TAF (≥ 18 Years of Age) NCT02276612 · Phase 2/3 · registry result, not featured evidence 21.2%Group 1: SC LEN+(F/TAF→ TAF) NCT04143594 · Phase 2 · registry result, not featured evidence · combination 34%Group 2: SC LEN + (F/TAF → BIC) NCT04143594 · Phase 2 · registry result, not featured evidence · combination 30.8%Group 3: Oral LEN + F/TAF NCT04143594 · Phase 2 · registry result, not featured evidence · combination 4.6%BIC + F/TAF NCT02397694 · Phase 2 · registry result, not featured evidence · combination —BIC + F/TAF (Double-Blind Randomiz NCT02397694 · Phase 2 · registry result, not featured evidence · combination 5.3% NCT01497899 · Phase 2 · registry result, not featured evidence 19.4% NCT01565850 · Phase 2 · registry result, not featured evidence 3% NCT03960645 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | —i NCT04982445 · Phase 4 · registry result, not featured evidence show 45 more results—400 mg + 600 mg Q4W NCT05896748 · Phase 3 · registry result, not featured evidence · combination —400 mg + 600 mg Q4W NCT05896748 · Phase 3 · registry result, not featured evidence · combination —400 mg + 600 mg Q4W NCT05896748 · Phase 3 · registry result, not featured evidence · combination —400 mg + 600 mg Q4W NCT05896748 · Phase 3 · registry result, not featured evidence · combination 1.1%Direct to Injections (D2I) NCT04542070 · Phase 3 · registry result, not featured evidence 5.7%Oral lead-in Phase (OLI) NCT04542070 · Phase 3 · registry result, not featured evidence —Q2M NCT04542070 · Phase 3 · registry result, not featured evidence 3.5% NCT04399551 · Phase 3 · registry result, not featured evidence 4.3% NCT04001803 · Phase 3 · registry result, not featured evidence —CAB LA + VRC07-523LS NCT03739996 · Phase 2 · registry result, not featured evidence · combination —Step 2: CAB LA + VRC07-523LS NCT03739996 · Phase 2 · registry result, not featured evidence · combination —IM-Q4W NCT02120352 · Phase 2 · registry result, not featured evidence · combination —IM-Q4W NCT02120352 · Phase 2 · registry result, not featured evidence · combination —IM-Q8W NCT02120352 · Phase 2 · registry result, not featured evidence · combination —IM-Q8W NCT02120352 · Phase 2 · registry result, not featured evidence · combination 1.1%Q2M NCT03639311 · Phase 2 · registry result, not featured evidence · combination 1.7%30 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled —30 mg NCT01641809 · Phase 2 · registry result, not featured evidence —30 mg NCT01641809 · Phase 2 · registry result, not featured evidence —30 mg NCT01641809 · Phase 2 · registry result, not featured evidence 4.9%60 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled —60 mg NCT01641809 · Phase 2 · registry result, not featured evidence —60 mg NCT01641809 · Phase 2 · registry result, not featured evidence —60 mg NCT01641809 · Phase 2 · registry result, not featured evidence 0%10 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled —10 mg NCT01641809 · Phase 2 · registry result, not featured evidence —10 mg NCT01641809 · Phase 2 · registry result, not featured evidence —10 mg NCT01641809 · Phase 2 · registry result, not featured evidence 12.5%30 mg NCT00920426 · Phase 2 · registry result, not featured evidence —5 mg NCT00920426 · Phase 2 · registry result, not featured evidence —30 mg NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 1 (C1) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 1 (C1) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 2 (C2) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 2 (C2) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 3 (C3) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 3 (C3) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 4 (C4) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 4 (C4) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 1: Cohort 4h (C4h) CAB200 + r NCT04484337 · Phase 1 · registry result, not featured evidence · combination —Part 1: Cohort 4h (C4h) CAB400 + r NCT04484337 · Phase 1 · registry result, not featured evidence · combination —Part 2: Cohort 5 (C5) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence —Part 2: Cohort 5 (C5) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence —30 mg NCT03149848 · Phase 1 · registry result, not featured evidence —300 mg + 30 mg NCT03149848 · Phase 1 · registry result, not featured evidence · combination | 1.5%F/TAF + 3rd Agentj NCT02121795 · Phase 3 · combination show 52 more results—F/TAF + 3rd Agent (Double-Blind) NCT02121795 · Phase 3 · combination —Open-Label F/TAF From F/TAF NCT02121795 · Phase 3 —Open-Label F/TAF From FTC/TDF NCT02121795 · Phase 3 4.2%F/TAF NCT02469246 · Phase 3 —F/TAF (Double-Blind Phase) NCT02469246 · Phase 3 —Open-Label F/TAF From ABC/3TC NCT02469246 · Phase 3 —Open-Label F/TAF From F/TAF NCT02469246 · Phase 3 0.7%E/C/F/TAF NCT01797445 · Phase 3 —E/C/F/TAF (Double-Blind Phase) NCT01797445 · Phase 3 —Open-Label E/C/F/TAF From E/C/F/TA NCT01797445 · Phase 3 —Open-Label E/C/F/TAF From E/C/F/TD NCT01797445 · Phase 3 0.7%E/C/F/TAF NCT01815736 · Phase 3 —Extension Phase: E/C/F/TAF From E/ NCT01815736 · Phase 3 —Extension Phase: E/C/F/TAF From SB NCT01815736 · Phase 3 —Randomized Phase: E/C/F/TAF NCT01815736 · Phase 3 2.8%Cohort 1 (Treatment-experienced) NCT01818596 · Phase 3 0%Cohort 2 (Treatment-naive) NCT01818596 · Phase 3 —Cohort 1: Age 12 to < 18 Years and NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3 —Cohort 2: Age 6 to < 12 Years and NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3 —Cohort 3: Age ≥ 2 Years and Weight NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3 — NCT04782180 · Phase 4 · registry result, not featured evidence 1.2% NCT02607956 · Phase 3 · registry result, not featured evidence · HIV · phase 3 0%B/F/TAF NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —B/F/TAF to B/F/TAF NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3 1.1%B/F/TAF NCT03110380 · Phase 3 · registry result, not featured evidence —Double-Blind Treatment Phase B/F/T NCT03110380 · Phase 3 · registry result, not featured evidence —Open-label Extension Phase B/F/TAF NCT03110380 · Phase 3 · registry result, not featured evidence —Open-label Extension Phase B/F/TAF NCT03110380 · Phase 3 · registry result, not featured evidence · combination —DB STB to OL STB NCT01705574 · Phase 3 · registry result, not featured evidence —Double-Blind: STB NCT01705574 · Phase 3 · registry result, not featured evidence 0.9% NCT02616783 · Phase 3 · registry result, not featured evidence —Delayed E/C/F/TAF NCT02605954 · Phase 3 · registry result, not featured evidence 2.7%E/C/F/TAF NCT02605954 · Phase 3 · registry result, not featured evidence —E/C/F/TAF + LDV/SOF NCT02707601 · Phase 3 · registry result, not featured evidence · combination —F/R/TAF + LDV/SOF NCT02707601 · Phase 3 · registry result, not featured evidence · combination —Part 1 Randomized Cohort TAF NCT01967940 · Phase 3 · registry result, not featured evidence —Part 1 Sentinel Cohort TAF NCT01967940 · Phase 3 · registry result, not featured evidence —Part 2 E/C/F/TAF + ATV NCT01967940 · Phase 3 · registry result, not featured evidence · combination —HIV-Suppressed NCT02071082 · Phase 3 · registry result, not featured evidence —HIV/HBV Treatment-Naive NCT02071082 · Phase 3 · registry result, not featured evidence —Cohort 1: E/C/F/TAF+DRV NCT01968551 · Phase 3 · registry result, not featured evidence · combination —Cohort 2: E/C/F/TAF+DRV NCT01968551 · Phase 3 · registry result, not featured evidence · combination —E/C/F/TAF (12 - 17 Years of Age) NCT02276612 · Phase 2/3 · registry result, not featured evidence —E/C/F/TAF (≥ 18 Years of Age) NCT02276612 · Phase 2/3 · registry result, not featured evidence 1.9%Group 1: SC LEN+(F/TAF→ TAF) NCT04143594 · Phase 2 · registry result, not featured evidence · combination 0%Group 2: SC LEN + (F/TAF → BIC) NCT04143594 · Phase 2 · registry result, not featured evidence · combination 0%Group 3: Oral LEN + F/TAF NCT04143594 · Phase 2 · registry result, not featured evidence · combination 1.5%BIC + F/TAF NCT02397694 · Phase 2 · registry result, not featured evidence · combination —BIC + F/TAF (Double-Blind Randomiz NCT02397694 · Phase 2 · registry result, not featured evidence · combination 0.9% NCT01497899 · Phase 2 · registry result, not featured evidence 0% NCT01565850 · Phase 2 · registry result, not featured evidence — NCT03960645 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 0%i NCT04982445 · Phase 4 · registry result, not featured evidence show 45 more results0%400 mg + 600 mg Q4W NCT05896748 · Phase 3 · registry result, not featured evidence · combination 0%400 mg + 600 mg Q4W NCT05896748 · Phase 3 · registry result, not featured evidence · combination 1.1%400 mg + 600 mg Q4W NCT05896748 · Phase 3 · registry result, not featured evidence · combination —400 mg + 600 mg Q4W NCT05896748 · Phase 3 · registry result, not featured evidence · combination 3.6%Direct to Injections (D2I) NCT04542070 · Phase 3 · registry result, not featured evidence 6.3%Oral lead-in Phase (OLI) NCT04542070 · Phase 3 · registry result, not featured evidence 3.4%Q2M NCT04542070 · Phase 3 · registry result, not featured evidence 4% NCT04399551 · Phase 3 · registry result, not featured evidence 7.8% NCT04001803 · Phase 3 · registry result, not featured evidence —CAB LA + VRC07-523LS NCT03739996 · Phase 2 · registry result, not featured evidence · combination 12.7%Step 2: CAB LA + VRC07-523LS NCT03739996 · Phase 2 · registry result, not featured evidence · combination 27%IM-Q4W NCT02120352 · Phase 2 · registry result, not featured evidence · combination 10%IM-Q4W NCT02120352 · Phase 2 · registry result, not featured evidence · combination 27%IM-Q8W NCT02120352 · Phase 2 · registry result, not featured evidence · combination 26.5%IM-Q8W NCT02120352 · Phase 2 · registry result, not featured evidence · combination 11.1%Q2M NCT03639311 · Phase 2 · registry result, not featured evidence · combination —30 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled 0%30 mg NCT01641809 · Phase 2 · registry result, not featured evidence 9.4%30 mg NCT01641809 · Phase 2 · registry result, not featured evidence 17%30 mg NCT01641809 · Phase 2 · registry result, not featured evidence —60 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled 3.3%60 mg NCT01641809 · Phase 2 · registry result, not featured evidence 9.1%60 mg NCT01641809 · Phase 2 · registry result, not featured evidence 9.8%60 mg NCT01641809 · Phase 2 · registry result, not featured evidence —10 mg NCT01641809 · Phase 2 · registry result, not featured evidence · pooled 3.3%10 mg NCT01641809 · Phase 2 · registry result, not featured evidence 9.6%10 mg NCT01641809 · Phase 2 · registry result, not featured evidence 15.2%10 mg NCT01641809 · Phase 2 · registry result, not featured evidence 0%30 mg NCT00920426 · Phase 2 · registry result, not featured evidence 0%5 mg NCT00920426 · Phase 2 · registry result, not featured evidence 0%30 mg NCT04484337 · Phase 1 · registry result, not featured evidence 0%Part 1: Cohort 1 (C1) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence 0%Part 1: Cohort 1 (C1) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence 0%Part 1: Cohort 2 (C2) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence 0%Part 1: Cohort 2 (C2) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence 0%Part 1: Cohort 3 (C3) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence 12.5%Part 1: Cohort 3 (C3) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence 0%Part 1: Cohort 4 (C4) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence 0%Part 1: Cohort 4 (C4) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence 0%Part 1: Cohort 4h (C4h) CAB200 + r NCT04484337 · Phase 1 · registry result, not featured evidence · combination 0%Part 1: Cohort 4h (C4h) CAB400 + r NCT04484337 · Phase 1 · registry result, not featured evidence · combination 0%Part 2: Cohort 5 (C5) CAB200 NCT04484337 · Phase 1 · registry result, not featured evidence 0%Part 2: Cohort 5 (C5) CAB400 NCT04484337 · Phase 1 · registry result, not featured evidence 0%30 mg NCT03149848 · Phase 1 · registry result, not featured evidence 7.1%300 mg + 30 mg NCT03149848 · Phase 1 · registry result, not featured evidence · combination | —F/TAF + 3rd Agentj NCT02121795 · Phase 3 · combination show 52 more results8.7%F/TAF + 3rd Agent (Double-Blind) NCT02121795 · Phase 3 · combination 6.1%Open-Label F/TAF From F/TAF NCT02121795 · Phase 3 9.7%Open-Label F/TAF From FTC/TDF NCT02121795 · Phase 3 —F/TAF NCT02469246 · Phase 3 19.6%F/TAF (Double-Blind Phase) NCT02469246 · Phase 3 0%Open-Label F/TAF From ABC/3TC NCT02469246 · Phase 3 0%Open-Label F/TAF From F/TAF NCT02469246 · Phase 3 —E/C/F/TAF NCT01797445 · Phase 3 12.5%E/C/F/TAF (Double-Blind Phase) NCT01797445 · Phase 3 2.8%Open-Label E/C/F/TAF From E/C/F/TA NCT01797445 · Phase 3 1.7%Open-Label E/C/F/TAF From E/C/F/TD NCT01797445 · Phase 3 —E/C/F/TAF NCT01815736 · Phase 3 3%Extension Phase: E/C/F/TAF From E/ NCT01815736 · Phase 3 5.2%Extension Phase: E/C/F/TAF From SB NCT01815736 · Phase 3 8.2%Randomized Phase: E/C/F/TAF NCT01815736 · Phase 3 22.7%Cohort 1 (Treatment-experienced) NCT01818596 · Phase 3 16.7%Cohort 2 (Treatment-naive) NCT01818596 · Phase 3 20%Cohort 1: Age 12 to < 18 Years and NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3 13.5%Cohort 2: Age 6 to < 12 Years and NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3 3.7%Cohort 3: Age ≥ 2 Years and Weight NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3 0% NCT04782180 · Phase 4 · registry result, not featured evidence 20% NCT02607956 · Phase 3 · registry result, not featured evidence · HIV · phase 3 14%B/F/TAF NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3 7.5%B/F/TAF to B/F/TAF NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —B/F/TAF NCT03110380 · Phase 3 · registry result, not featured evidence 12.7%Double-Blind Treatment Phase B/F/T NCT03110380 · Phase 3 · registry result, not featured evidence 9.6%Open-label Extension Phase B/F/TAF NCT03110380 · Phase 3 · registry result, not featured evidence 9.5%Open-label Extension Phase B/F/TAF NCT03110380 · Phase 3 · registry result, not featured evidence · combination 5.3%DB STB to OL STB NCT01705574 · Phase 3 · registry result, not featured evidence 8.7%Double-Blind: STB NCT01705574 · Phase 3 · registry result, not featured evidence 9.1% NCT02616783 · Phase 3 · registry result, not featured evidence 4.5%Delayed E/C/F/TAF NCT02605954 · Phase 3 · registry result, not featured evidence 6.6%E/C/F/TAF NCT02605954 · Phase 3 · registry result, not featured evidence 9.5%E/C/F/TAF + LDV/SOF NCT02707601 · Phase 3 · registry result, not featured evidence · combination 16.2%F/R/TAF + LDV/SOF NCT02707601 · Phase 3 · registry result, not featured evidence · combination 10.7%Part 1 Randomized Cohort TAF NCT01967940 · Phase 3 · registry result, not featured evidence 0%Part 1 Sentinel Cohort TAF NCT01967940 · Phase 3 · registry result, not featured evidence 10.8%Part 2 E/C/F/TAF + ATV NCT01967940 · Phase 3 · registry result, not featured evidence · combination 16.2%HIV-Suppressed NCT02071082 · Phase 3 · registry result, not featured evidence 0%HIV/HBV Treatment-Naive NCT02071082 · Phase 3 · registry result, not featured evidence 4.8%Cohort 1: E/C/F/TAF+DRV NCT01968551 · Phase 3 · registry result, not featured evidence · combination 10.1%Cohort 2: E/C/F/TAF+DRV NCT01968551 · Phase 3 · registry result, not featured evidence · combination 6%E/C/F/TAF (12 - 17 Years of Age) NCT02276612 · Phase 2/3 · registry result, not featured evidence 0%E/C/F/TAF (≥ 18 Years of Age) NCT02276612 · Phase 2/3 · registry result, not featured evidence 7.7%Group 1: SC LEN+(F/TAF→ TAF) NCT04143594 · Phase 2 · registry result, not featured evidence · combination 7.5%Group 2: SC LEN + (F/TAF → BIC) NCT04143594 · Phase 2 · registry result, not featured evidence · combination 13.5%Group 3: Oral LEN + F/TAF NCT04143594 · Phase 2 · registry result, not featured evidence · combination —BIC + F/TAF NCT02397694 · Phase 2 · registry result, not featured evidence · combination 6.2%BIC + F/TAF (Double-Blind Randomiz NCT02397694 · Phase 2 · registry result, not featured evidence · combination 10.7% NCT01497899 · Phase 2 · registry result, not featured evidence 4.9% NCT01565850 · Phase 2 · registry result, not featured evidence 18.2% NCT03960645 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | i injection site discomfort 13.6% injection site pain 13.6% fatigue 2.3% NCT04982445 · Phase 4 · registry result, not featured evidence show 40 more results400 mg + 600 mg Q4W injection site pain 32.3% injection site nodule 9.7% injection site induration 2.2% NCT05896748 · Phase 3 · registry result, not featured evidence · combination 400 mg + 600 mg Q4W injection site pain 74.2% injection site nodule 64.5% injection site erythema 51.6% NCT05896748 · Phase 3 · registry result, not featured evidence · combination 400 mg + 600 mg Q4W injection site pain 30.9% injection site nodule 3.2% injection site pruritus 2.1% NCT05896748 · Phase 3 · registry result, not featured evidence · combination injection site pain 65.2% covid-19 17.9% headache 12.5% NCT04542070 · Phase 3 · registry result, not featured evidence injection site pain 60.6% covid-19 19.4% injection site induration 11.4% NCT04542070 · Phase 3 · registry result, not featured evidence Q2M injection site pain 37.9% covid-19 14.5% arthralgia 0% NCT04542070 · Phase 3 · registry result, not featured evidence injection site pain 80.2% covid-19 18.4% injection site induration 11.2% NCT04399551 · Phase 3 · registry result, not featured evidence injection site pain 55.7% injection site discomfort 26.1% fatigue 20% NCT04001803 · Phase 3 · registry result, not featured evidence creatinine renal clearance decreased 19.7% lipase increased 11.3% chills 7% NCT03739996 · Phase 2 · registry result, not featured evidence · combination IM-Q4W injection site pain 99.1% injection site nodule 49.6% nasopharyngitis 47% NCT02120352 · Phase 2 · registry result, not featured evidence · combination IM-Q4W injection site pain 80% injection site nodule 50% nasopharyngitis 50% NCT02120352 · Phase 2 · registry result, not featured evidence · combination IM-Q8W injection site pain 96.5% nasopharyngitis 47% injection site nodule 40% NCT02120352 · Phase 2 · registry result, not featured evidence · combination IM-Q8W injection site pain 91.2% injection site nodule 35.3% covid-19 26.5% NCT02120352 · Phase 2 · registry result, not featured evidence · combination Q2M injection site pain 74.4% covid-19 33.3% upper respiratory tract infection 17.8% NCT03639311 · Phase 2 · registry result, not featured evidence · combination 30 mg headache 21.7% nausea 18.3% upper respiratory tract infection 13.3% NCT01641809 · Phase 2 · registry result, not featured evidence 30 mg upper respiratory tract infection 26.4% diarrhoea 13.2% rash 11.3% NCT01641809 · Phase 2 · registry result, not featured evidence 30 mg upper respiratory tract infection 31.9% back pain 12.8% oropharyngeal pain 12.8% NCT01641809 · Phase 2 · registry result, not featured evidence 60 mg headache 21.3% diarrhoea 18% nausea 18% NCT01641809 · Phase 2 · registry result, not featured evidence 60 mg upper respiratory tract infection 21.8% nausea 14.5% bronchitis 10.9% NCT01641809 · Phase 2 · registry result, not featured evidence 60 mg upper respiratory tract infection 27.5% anxiety 11.8% sinusitis 11.8% NCT01641809 · Phase 2 · registry result, not featured evidence 10 mg nausea 23.3% headache 21.7% diarrhoea 16.7% NCT01641809 · Phase 2 · registry result, not featured evidence 10 mg upper respiratory tract infection 17.3% depression 9.6% diarrhoea 9.6% NCT01641809 · Phase 2 · registry result, not featured evidence 10 mg diarrhoea 13% nasopharyngitis 10.9% gonorrhoea 8.7% NCT01641809 · Phase 2 · registry result, not featured evidence 30 mg dizziness 37.5% (placebo 0%) dyspepsia 25% (placebo 0%) headache 25% (placebo 0%) NCT00920426 · Phase 2 · registry result, not featured evidence 5 mg abdominal pain 0% (placebo 0%) abnormal dreams 0% (placebo 0%) blood bilirubin increased 0% (placebo 50%) NCT00920426 · Phase 2 · registry result, not featured evidence 30 mg atrioventricular block first degree 7.7% decreased appetite 7.7% headache 7.7% NCT04484337 · Phase 1 · registry result, not featured evidence injection site pain 100% aspartate aminotransferase increased 50% blood creatine phosphokinase increased 50% NCT04484337 · Phase 1 · registry result, not featured evidence injection site pain 100% injection site nodule 55.6% injection site erythema 44.4% NCT04484337 · Phase 1 · registry result, not featured evidence injection site haemorrhage 100% injection site nodule 100% injection site pain 100% NCT04484337 · Phase 1 · registry result, not featured evidence injection site erythema 72.7% injection site pain 72.7% injection site induration 45.5% NCT04484337 · Phase 1 · registry result, not featured evidence injection site induration 100% injection site pain 100% injection site bruising 50% NCT04484337 · Phase 1 · registry result, not featured evidence injection site pain 75% headache 37.5% injection site swelling 37.5% NCT04484337 · Phase 1 · registry result, not featured evidence catheter site bruise 50% injection site erythema 50% injection site induration 50% NCT04484337 · Phase 1 · registry result, not featured evidence injection site erythema 100% injection site pain 94.4% headache 77.8% NCT04484337 · Phase 1 · registry result, not featured evidence injection site erythema 100% injection site pain 100% injection site pruritus 87.5% NCT04484337 · Phase 1 · registry result, not featured evidence · combination injection site erythema 100% injection site pain 100% injection site warmth 88.9% NCT04484337 · Phase 1 · registry result, not featured evidence · combination accident 100% injection site nodule 100% injection site pain 100% NCT04484337 · Phase 1 · registry result, not featured evidence injection site pain 100% injection site swelling 70% headache 60% NCT04484337 · Phase 1 · registry result, not featured evidence 30 mg blood creatine phosphokinase increased 6.7% contusion 6.7% body temperature increased 0% NCT03149848 · Phase 1 · registry result, not featured evidence 300 mg + 30 mg body temperature increased 7.1% headache 7.1% hyperkeratosis 7.1% NCT03149848 · Phase 1 · registry result, not featured evidence · combination | j upper respiratory tract infection 16.2% diarrhoea 13.2% nasopharyngitis 12.9% NCT02121795 · Phase 3 · combination show 45 more resultsupper respiratory tract infection 40% respiratory tract infection 38% nausea 30% NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3 upper respiratory tract infection 26.9% vomiting 25% respiratory tract infection 21.2% NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3 upper respiratory tract infection 51.9% cough 33.3% nasopharyngitis 18.5% NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3 diarrhoea 20.6% headache 17.8% nasopharyngitis 15.9% NCT02607956 · Phase 3 · registry result, not featured evidence · HIV · phase 3 diarrhoea 17.2% upper respiratory tract infection 14.6% headache 14% NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3 syphilis 8.7% covid-19 7.9% nasopharyngitis 7.1% NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3 nasopharyngitis 15.5% upper respiratory tract infection 11.6% diarrhoea 9.2% NCT03110380 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 7.2% arthralgia 3.2% bronchitis 3.2% NCT03110380 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 8.6% diarrhoea 6% fatigue 6% NCT03110380 · Phase 3 · registry result, not featured evidence · combination upper respiratory tract infection 14.6% headache 11% anaemia 7.3% NCT01705574 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 17.3% headache 17% nausea 14.9% NCT01705574 · Phase 3 · registry result, not featured evidence nasopharyngitis 10.9% back pain 8.2% diarrhoea 7.3% NCT02616783 · Phase 3 · registry result, not featured evidence arthralgia 9% diarrhoea 4.5% headache 4.5% NCT02605954 · Phase 3 · registry result, not featured evidence diarrhoea 10.4% headache 8.2% vitamin d deficiency 7.1% NCT02605954 · Phase 3 · registry result, not featured evidence urinary tract infection 13.5% upper respiratory tract infection 12.2% arthralgia 9.5% NCT02707601 · Phase 3 · registry result, not featured evidence · combination cough 13.5% headache 10.8% nausea 8.1% NCT02707601 · Phase 3 · registry result, not featured evidence · combination hyperbilirubinaemia 3.6% (placebo 0%) influenza 3.6% (placebo 0%) jaundice 3.6% (placebo 0%) NCT01967940 · Phase 3 · registry result, not featured evidence nausea 16.7% (placebo 0%) arthralgia 8.3% (placebo 0%) diarrhoea 8.3% (placebo 0%) NCT01967940 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 29.7% (placebo 0%) malaria 13.5% (placebo 0%) headache 10.8% (placebo 0%) NCT01967940 · Phase 3 · registry result, not featured evidence · combination upper respiratory tract infection 23% nasopharyngitis 12.2% diarrhoea 10.8% NCT02071082 · Phase 3 · registry result, not featured evidence dental caries 33.3% diarrhoea 33.3% herpes zoster 33.3% NCT02071082 · Phase 3 · registry result, not featured evidence acute sinusitis 19% bronchitis 14.3% sinusitis 14.3% NCT01968551 · Phase 3 · registry result, not featured evidence · combination back pain 12.4% upper respiratory tract infection 11.2% bronchitis 6.7% NCT01968551 · Phase 3 · registry result, not featured evidence · combination cough 24% upper respiratory tract infection 22% vomiting 16% NCT02276612 · Phase 2/3 · registry result, not featured evidence upper respiratory tract infection 60% cough 50% nasal obstruction 30% NCT02276612 · Phase 2/3 · registry result, not featured evidence injection site erythema 48.1% injection site swelling 32.7% injection site pain 28.8% NCT04143594 · Phase 2 · registry result, not featured evidence · combination injection site erythema 34% injection site swelling 34% injection site pain 26.4% NCT04143594 · Phase 2 · registry result, not featured evidence · combination covid-19 21.2% influenza 21.2% headache 17.3% NCT04143594 · Phase 2 · registry result, not featured evidence · combination diarrhoea 13.8% upper respiratory tract infection 10.8% headache 9.2% NCT02397694 · Phase 2 · registry result, not featured evidence · combination nausea 22.3% diarrhoea 17% fatigue 16.1% NCT01497899 · Phase 2 · registry result, not featured evidence diarrhoea 21.4% upper respiratory tract infection 15.5% fatigue 13.6% NCT01565850 · Phase 2 · registry result, not featured evidence back pain 12.1% gestational diabetes 12.1% anaemia 9.1% NCT03960645 · Phase 1 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bTrial phases differ: Phase 2 versus Phase 2/3.
- cPopulation comparability has not been reviewed for both studies.
- dTreatment context differs: pooled versus combination.
- eAssessment timepoints differ: 324 weeks versus 48 weeks.
- fTrial phases differ: Phase 2 versus Phase 3.
- gTreatment context has not been resolved for both arms.
- hAssessment timepoints differ: 52 weeks versus 144 weeks.
- iPopulation comparability has not been reviewed for these studies.
- jPopulation comparability has not been reviewed for 47 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Cabotegravir/rilpivirine (Cabenuva)
show 2 more results
show 2 more results
show 1 more result
show 6 more results
show 25 more results
show 1 more result
show 1 more result
show 1 more result
show 6 more results
show 1 more result
+ 163 further endpoints in the CSV export.
Tenofovir alafenamide/emtricitabine
show 6 more results
show 9 more results
show 1 more result
show 5 more results
show 2 more results
show 5 more results
show 4 more results
show 2 more results
show 1 more result
+ 14 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Cabotegravir/rilpivirine (Cabenuva)'s landscape · Tenofovir alafenamide/emtricitabine's landscape